Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. It markets products in more than 100 countries and in 2011 the company generated sales of almost € 10 billion. More than 37,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,500 in research and development alone.
Operations are concentrated on five big therapeutic groups:
Cardiovascular and blood diseases
We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business.
Age-related macular degeneration (AMD)
Central retinal vein occlusion (CRVO)
Colorectal Cancer (CRC)
Diabetic macular edema (DME)
Gastrointestinal stromal tumor (GIST)
Heart attack and stroke
High blood pressure
Peripheral arterial occlusive disease
Premenstrual dysphoric disorder (PMDD)
Pulmonary arterial hypertension
Renal cell carcinoma
In its internal research for active ingredients, Bayer HealthCare Pharmaceuticals concentrates on four core areas: Oncology, Cardiology, Women´s Healthcare, and Diagnostic Imaging. With new approaches in cancer therapy, cardiovascular diseases, gynecological therapies, and molecular imaging, we aim to become the innovation leader in these areas.